Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,128,865
  • Shares Outstanding, K 111,490
  • Annual Sales, $ 74,910 K
  • Annual Income, $ -761,500 K
  • 60-Month Beta 2.37
  • Price/Sales 137.60
  • Price/Cash Flow N/A
  • Price/Book 6.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -2.20
  • Number of Estimates 5
  • High Estimate -1.92
  • Low Estimate -2.39
  • Prior Year -2.09
  • Growth Rate Est. (year over year) -5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.26 +15.74%
on 10/14/19
93.98 -3.62%
on 11/08/19
+11.61 (+14.70%)
since 10/11/19
3-Month
73.32 +23.54%
on 10/02/19
93.98 -3.62%
on 11/08/19
+10.58 (+13.23%)
since 08/13/19
52-Week
60.27 +50.29%
on 12/24/18
96.08 -5.72%
on 04/01/19
+23.27 (+34.57%)
since 11/13/18

Most Recent Stories

More News
Alnylam Pharmace Set to Possibly Rebound After Yesterday's Selloff of 1.09%

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $89.75 to a high of $90.97. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of...

ALNY : 90.58 (-0.30%)
Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2019 Healthcare Conference on Tuesday,...

ALNY : 90.58 (-0.30%)
Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

--a^' In Phase 2 OLE, Lumasiran Treatment Resulted in 76 percent Mean Maximal Reduction in Urinary Oxalate Relative to Phase 1/2 Baseline -

ALNY : 90.58 (-0.30%)
Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy?

Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

ALNY : 90.58 (-0.30%)
Shares of ALNY Up 7.3% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Alnylam Pharmace (NASDAQ:ALNY) on October 21st, 2019 at $85.25. In approximately 2 weeks, Alnylam Pharmace has returned 7.31% as of today's recent price of $91.48.

ALNY : 90.58 (-0.30%)
Alnylam (ALNY) Upgraded to Buy: Here's Why

Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ALNY : 90.58 (-0.30%)
Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength

Regeneron (REGN) beats on Q3 earnings and sales on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.

BAYRY : 19.3800 (unch)
SNY : 45.62 (-0.93%)
ALNY : 90.58 (-0.30%)
REGN : 348.30 (-0.03%)
Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates

Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

SNY : 45.62 (-0.93%)
ALNY : 90.58 (-0.30%)
REGN : 348.30 (-0.03%)
MDCO : 52.81 (-1.09%)
Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss

The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.

MRK : 84.82 (+0.83%)
ALNY : 90.58 (-0.30%)
MDCO : 52.81 (-1.09%)
ACOR : 1.93 (-2.53%)
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 11.52% and 14.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ALNY : 90.58 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ALNY with:

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 92.96
1st Resistance Point 91.77
Last Price 90.58
1st Support Level 89.57
2nd Support Level 88.56

See More

52-Week High 96.08
Last Price 90.58
Fibonacci 61.8% 82.40
Fibonacci 50% 78.18
Fibonacci 38.2% 73.95
52-Week Low 60.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar